Clinical characteristics of patients
| Characteristics . | Whole cohort, N = 94 . | Responders, n = 40 . | Nonresponders, n = 54 . | P . |
|---|---|---|---|---|
| Age | ||||
| Median, y (IQR) | 73 (67–76) | 73 (69–77) | 73 (66–76) | .519 |
| Gender | ||||
| Male, n (%) | 67 (71.3) | 30 (73.2) | 37 (63.8) | .645 |
| WHO subtype, n (%) | ||||
| RA | 3 (3.2) | 2 (5.0) | 1 (1.8) | .386 |
| RARS | 46 (48.9) | 17 (42.5) | 29 (53.7) | |
| RCMD-RS | 15 (16.0) | 5 (12.5) | 10 (25.0) | |
| RCMD | 12 (12.8) | 9 (22.5) | 3 (7.5) | |
| RAEB-1 | 16 (17.0) | 7 (17.5) | 9 (22.5) | |
| MDS-U | 2 (2.1) | 0 (0.0) | 2 (5.0) | |
| Hemoglobin, g/L | ||||
| Median (IQR) | 8.1 (7.6–8.7) | 8.1 (7.6–8.6) | 8.1 (7.6–8.7) | .756 |
| Neutrophil count, g/L | ||||
| Median (IQR) | 2.2 (1.4–3.4) | 1.6 (1.1–2.8) | 2.4 (1.7–3.5) | .119 |
| Platelet count, g/L | ||||
| Median (IQR) | 231 (170–325) | 241 (159–304) | 230 (170–344) | .443 |
| BM blasts, % | ||||
| Median (IQR) | 2 (1–4) | 2 (1.9–4) | 2 (1–3.7) | .118 |
| BM erythroblast, % | ||||
| Median (IQR) | 30 (19–45) | 39 (20–48) | 29 (18–43) | .210 |
| BM ring sideroblasts | ||||
| >15%, n (%) | 63/69 (91) | 24/25 (96) | 39/44 (89) | .406 |
| Karyotype, n (%) | ||||
| Favorable | 79 (84.1) | 32 (80.0) | 47 (87.0) | .462 |
| Intermediate | 13 (13.8) | 7 (17.5) | 6 (11.1) | |
| Unavailable | 2 (2.1) | 1 (2.5) | 1 (1.9) | |
| IPSS, n (%) | ||||
| Low risk | 44 (46.8) | 14 (35.0) | 30 (55.5) | .499 |
| Int-1 | 48 (51.1) | 25 (62.5) | 23 (42.6) | |
| Unavailable | 2 (2.1) | 1 (2.5) | 1 (1.9) | |
| Serum erythropoietin level, U/L | ||||
| Median (IQR) | 190 (76–407) | 108 (59–228) | 269 (102–689) | .306 |
| Characteristics . | Whole cohort, N = 94 . | Responders, n = 40 . | Nonresponders, n = 54 . | P . |
|---|---|---|---|---|
| Age | ||||
| Median, y (IQR) | 73 (67–76) | 73 (69–77) | 73 (66–76) | .519 |
| Gender | ||||
| Male, n (%) | 67 (71.3) | 30 (73.2) | 37 (63.8) | .645 |
| WHO subtype, n (%) | ||||
| RA | 3 (3.2) | 2 (5.0) | 1 (1.8) | .386 |
| RARS | 46 (48.9) | 17 (42.5) | 29 (53.7) | |
| RCMD-RS | 15 (16.0) | 5 (12.5) | 10 (25.0) | |
| RCMD | 12 (12.8) | 9 (22.5) | 3 (7.5) | |
| RAEB-1 | 16 (17.0) | 7 (17.5) | 9 (22.5) | |
| MDS-U | 2 (2.1) | 0 (0.0) | 2 (5.0) | |
| Hemoglobin, g/L | ||||
| Median (IQR) | 8.1 (7.6–8.7) | 8.1 (7.6–8.6) | 8.1 (7.6–8.7) | .756 |
| Neutrophil count, g/L | ||||
| Median (IQR) | 2.2 (1.4–3.4) | 1.6 (1.1–2.8) | 2.4 (1.7–3.5) | .119 |
| Platelet count, g/L | ||||
| Median (IQR) | 231 (170–325) | 241 (159–304) | 230 (170–344) | .443 |
| BM blasts, % | ||||
| Median (IQR) | 2 (1–4) | 2 (1.9–4) | 2 (1–3.7) | .118 |
| BM erythroblast, % | ||||
| Median (IQR) | 30 (19–45) | 39 (20–48) | 29 (18–43) | .210 |
| BM ring sideroblasts | ||||
| >15%, n (%) | 63/69 (91) | 24/25 (96) | 39/44 (89) | .406 |
| Karyotype, n (%) | ||||
| Favorable | 79 (84.1) | 32 (80.0) | 47 (87.0) | .462 |
| Intermediate | 13 (13.8) | 7 (17.5) | 6 (11.1) | |
| Unavailable | 2 (2.1) | 1 (2.5) | 1 (1.9) | |
| IPSS, n (%) | ||||
| Low risk | 44 (46.8) | 14 (35.0) | 30 (55.5) | .499 |
| Int-1 | 48 (51.1) | 25 (62.5) | 23 (42.6) | |
| Unavailable | 2 (2.1) | 1 (2.5) | 1 (1.9) | |
| Serum erythropoietin level, U/L | ||||
| Median (IQR) | 190 (76–407) | 108 (59–228) | 269 (102–689) | .306 |
Clinical and biological characteristics were collected at the time of inclusion and compared between responders and nonresponders to treatment by lenalidomide or lenalidomide plus EPO. Perls staining was available in 69 of 94 (73%) patients.
Int-1, intermediate-1; IPSS, International Prognostic Scoring System; IQR, interquartile range; MDS-U, undefined MDS; RA, refractory anemia; RAEB1, refractory anemia with excess of blasts type 1; RARS, refractory anemia with ring sideroblasts; RCMD, refractory cytopenia with multilineage dysplasia; RCMD-RS, RCMD with ring sideroblasts; WHO, World Health Organization.